| 1 |
Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436.
DOI
ScienceOn
|
| 2 |
Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-338.
DOI
ScienceOn
|
| 3 |
Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006;124:175-189.
DOI
ScienceOn
|
| 4 |
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
DOI
ScienceOn
|
| 5 |
Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267:10931-10934.
|
| 6 |
Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660.
DOI
ScienceOn
|
| 7 |
Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-974.
DOI
ScienceOn
|
| 8 |
Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-936.
DOI
ScienceOn
|
| 9 |
Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-286.
DOI
ScienceOn
|
| 10 |
Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 2007;58:491-504.
DOI
ScienceOn
|
| 11 |
Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011;146:873-887.
DOI
ScienceOn
|
| 12 |
Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
DOI
ScienceOn
|
| 13 |
Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 2011;32:88-111.
DOI
ScienceOn
|
| 14 |
Stockmann C, Doedens A, Weidemann A, et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008;456:814-818.
DOI
ScienceOn
|
| 15 |
De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012;44:1-9.
DOI
ScienceOn
|
| 16 |
Tvorogov D, Anisimov A, Zheng W, et al. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 2010;18:630-640.
DOI
ScienceOn
|
| 17 |
Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010;140:460-476.
DOI
ScienceOn
|
| 18 |
Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-583.
DOI
ScienceOn
|
| 19 |
Tarallo V, Vesci L, Capasso O, et al. A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. Cancer Res 2010;70:1804-1813.
DOI
|
| 20 |
Rolny C, Mazzone M, Tugues S, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through down-regulation of PlGF. Cancer Cell 2011;19:31-44.
DOI
ScienceOn
|
| 21 |
Hagberg CE, Falkevall A, Wang X, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010;464:917-921.
DOI
ScienceOn
|
| 22 |
Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-840.
DOI
|
| 23 |
Bry M, Kivela R, Holopainen T, et al. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation 2010;122:1725-1733.
DOI
ScienceOn
|
| 24 |
De Falco S, Gigante B, Persico MG. Structure and function of placental growth factor. Trends Cardiovasc Med 2002;12:241-246.
DOI
ScienceOn
|
| 25 |
Hellberg C, Ostman A, Heldin CH. PDGF and vessel maturation. Recent Results Cancer Res 2010;180:103-114.
DOI
ScienceOn
|
| 26 |
Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008;8:942-956.
DOI
ScienceOn
|
| 27 |
Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B, Wu Y. Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (human antibody targeting vascular endothelial growth factor receptor-1). Cancer 2010;116(4 Suppl):1027-1032.
DOI
ScienceOn
|
| 28 |
Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685-693.
DOI
ScienceOn
|
| 29 |
Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005;7:870-879.
DOI
ScienceOn
|
| 30 |
di Tomaso E, London N, Fuja D, et al. PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS One 2009;4:e5123.
DOI
ScienceOn
|
| 31 |
Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-253.
DOI
ScienceOn
|
| 32 |
Murakami M, Nguyen LT, Zhuang ZW, et al. The FGF system has a key role in regulating vascular integrity. J Clin Invest 2008;118:3355-3366.
DOI
ScienceOn
|
| 33 |
Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009;10:165-177.
DOI
ScienceOn
|
| 34 |
Saharinen P, Eklund L, Miettinen J, et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 2008;10:527-537.
DOI
ScienceOn
|
| 35 |
De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-226.
DOI
ScienceOn
|
| 36 |
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
DOI
ScienceOn
|
| 37 |
Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell 2009;16:209-221.
DOI
ScienceOn
|
| 38 |
Mazzone M, Dettori D, Leite de Oliveira R, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009;136:839-851.
DOI
ScienceOn
|
| 39 |
Thurston G, Noguera-Troise I, Yancopoulos GD. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 2007;7:327-331.
DOI
ScienceOn
|
| 40 |
Mosch B, Reissenweber B, Neuber C, Pietzsch J. Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. J Oncol 2010; 2010:135285.
|
| 41 |
Gu C, Giraudo E. The role of semaphorins and their receptors in vascular development and cancer. Exp Cell Res 2013;319:1306-1316.
DOI
ScienceOn
|
| 42 |
Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-739.
DOI
ScienceOn
|
| 43 |
Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
|
| 44 |
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
DOI
ScienceOn
|
| 45 |
Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278-287.
DOI
ScienceOn
|
| 46 |
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
DOI
ScienceOn
|
| 47 |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
DOI
ScienceOn
|
| 48 |
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
DOI
ScienceOn
|
| 49 |
Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
DOI
ScienceOn
|
| 50 |
Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338.
DOI
ScienceOn
|
| 51 |
Ward JE, Stadler WM. Pazopanib in renal cell carcinoma. Clin Cancer Res 2010;16:5923-5927.
DOI
ScienceOn
|
| 52 |
Schoffski P. Pazopanib in the treatment of soft tissue sarcoma. Expert Rev Anticancer Ther 2012;12:711-723.
DOI
ScienceOn
|
| 53 |
Ho TH, Jonasch E. Axitinib in the treatment of metastatic renal cell carcinoma. Future Oncol 2011;7:1247-1253.
DOI
ScienceOn
|
| 54 |
Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-141.
DOI
|
| 55 |
Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31:3639-3646.
DOI
ScienceOn
|
| 56 |
Andre T, Dumont SN. Regorafenib approved in metastatic colorectal cancer. Bull Cancer 2013;100:1027-1029.
|
| 57 |
Lyseng-Williamson KA. Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib. BioDrugs 2013;27:525-531.
DOI
ScienceOn
|
| 58 |
Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48:257-293.
DOI
ScienceOn
|
| 59 |
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
DOI
ScienceOn
|
| 60 |
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
DOI
ScienceOn
|
| 61 |
Garnock-Jones KP. Ranibizumab: in macular oedema following retinal vein occlusion. Drugs 2011;71:455-463.
|
| 62 |
CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
DOI
ScienceOn
|
| 63 |
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week eesults of the VIEW studies. Ophthalmology 2013.
|
| 64 |
Famiglietti EV, Stopa EG, McGookin ED, Song P, LeBlanc V, Streeten BW. Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. Brain Res 2003;969:195-204.
DOI
ScienceOn
|
| 65 |
Sayanagi K, Sharma S, Kaiser PK. Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration. Br J Ophthalmol 2009;93:622-626.
DOI
ScienceOn
|
| 66 |
Yodoi Y, Tsujikawa A, Nakanishi H, et al. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2009;147:816-824.
DOI
ScienceOn
|
| 67 |
Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEATROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-615.
DOI
ScienceOn
|
| 68 |
Kimoto K, Kubota T. Anti-VEGF agents for ocular angiogenesis and vascular permeability. J Ophthalmol 2011;2012:852183.
|
| 69 |
Peeters M, Strickland AH, Lichinitser M, et al. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 2013;108:503-511.
DOI
ScienceOn
|
| 70 |
Besse B, Tsao LC, Chao DT, et al. Phase Ib safety and pharmacokinetic study of volociximab, an anti-alpha- 5beta1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 2013;24:90-96.
DOI
ScienceOn
|
| 71 |
Macdonald TJ, Vezina G, Stewart CF, et al. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol 2013;15:1438-1444.
DOI
ScienceOn
|
| 72 |
Wu Y, Zhong Z, Huber J, et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 2006;12:6573-6584.
DOI
ScienceOn
|
| 73 |
Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
DOI
ScienceOn
|
| 74 |
Ribatti D. The inefficacy of antiangiogenic therapies. J Angiogenes Res 2010;2:27.
DOI
ScienceOn
|
| 75 |
Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 2012;12:699-709.
DOI
ScienceOn
|
| 76 |
Verma S, McLeod D, Batist G, Robidoux A, Martins IR, Mackey JR. In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist 2011;16:25-35.
|
| 77 |
O'Connor R, Clynes M, Dowling P, O'Donovan N, O'Driscoll L. Drug resistance in cancer: searching for mechanisms, markers and therapeutic agents. Expert Opin Drug Metab Toxicol 2007;3:805-817.
DOI
ScienceOn
|
| 78 |
Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2:306-314.
DOI
|
| 79 |
Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13:206-220.
DOI
ScienceOn
|
| 80 |
Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-221.
DOI
|
| 81 |
Jakobsson L, Franco CA, Bentley K, et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol 2010;12:943-953.
DOI
ScienceOn
|
| 82 |
Ciombor KK, Berlin J, Chan E. Aflibercept. Clin Cancer Res 2013;19:1920-1925.
DOI
ScienceOn
|
| 83 |
Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther 2013;13:1187-1196.
DOI
ScienceOn
|
| 84 |
Crawford Y, Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 2009;335:261-269.
DOI
|
| 85 |
Gigante B, Morlino G, Gentile MT, Persico MG, De Falco S. Plgf-/-eNos-/- mice show defective angiogenesis associated with increased oxidative stress in response to tissue ischemia. FASEB J 2006;20:970-972.
DOI
ScienceOn
|
| 86 |
Ambati J, Atkinson JP, Gelfand BD. Immunology of age-related macular degeneration. Nat Rev Immunol 2013;13:438-451.
DOI
ScienceOn
|
| 87 |
Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007;130:691-703.
DOI
ScienceOn
|
webmaster
